DK175220B1 - Ciclosporin, fremgangsmåde til fremstilling deraf, farmaceutisk præparat med indhold deraf samt dets anvendelse - Google Patents

Ciclosporin, fremgangsmåde til fremstilling deraf, farmaceutisk præparat med indhold deraf samt dets anvendelse Download PDF

Info

Publication number: DK175220B1
Authority: DK; Denmark
Prior art keywords: ciclosporin; iii; orthorhombic; crystal; approx
Prior art date: 1987-12-21

Application number

DK198807054A

Other languages

Danish (da)

English (en)

Other versions

DK705488A (da

DK705488D0 (da

Inventor

Martin List

Danielle Giron

Freidrich Richter

Yasuyuki Uike

Hans Peter Weber

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1988-12-19

Publication date

2004-07-12

1988-12-19 Application filed by Novartis Ag filed Critical Novartis Ag

1988-12-19 Publication of DK705488D0 publication Critical patent/DK705488D0/da

1989-06-22 Publication of DK705488A publication Critical patent/DK705488A/da

2004-07-12 Application granted granted Critical

2004-07-12 Publication of DK175220B1 publication Critical patent/DK175220B1/da

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title claims description 145
108010036949 Cyclosporine Proteins 0.000 title claims description 144
229960001265 ciclosporin Drugs 0.000 title claims description 142
239000008194 pharmaceutical composition Substances 0.000 title claims description 10
238000000034 method Methods 0.000 title description 37
230000008569 process Effects 0.000 title description 11
239000000203 mixture Substances 0.000 claims description 72
238000002360 preparation method Methods 0.000 claims description 61
239000013078 crystal Substances 0.000 claims description 56
239000002245 particle Substances 0.000 claims description 55
230000000699 topical effect Effects 0.000 claims description 29
239000007924 injection Substances 0.000 claims description 25
238000002347 injection Methods 0.000 claims description 25
239000000243 solution Substances 0.000 claims description 16
238000002425 crystallisation Methods 0.000 claims description 11
230000008025 crystallization Effects 0.000 claims description 11
239000000463 material Substances 0.000 claims description 9
239000004480 active ingredient Substances 0.000 claims description 8
239000003085 diluting agent Substances 0.000 claims description 4
238000001802 infusion Methods 0.000 claims description 4
238000002441 X-ray diffraction Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
238000009966 trimming Methods 0.000 claims description 3
230000009969 flowable effect Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
239000013080 microcrystalline material Substances 0.000 claims 1
238000011282 treatment Methods 0.000 description 57
229930182912 cyclosporin Natural products 0.000 description 29
201000004681 Psoriasis Diseases 0.000 description 28
239000000047 product Substances 0.000 description 28
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
229930105110 Cyclosporin A Natural products 0.000 description 24
229920001223 polyethylene glycol Polymers 0.000 description 23
-1 polyalkyl ethers Chemical class 0.000 description 22
239000000499 gel Substances 0.000 description 19
229940068196 placebo Drugs 0.000 description 19
239000000902 placebo Substances 0.000 description 19
201000010099 disease Diseases 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
238000012360 testing method Methods 0.000 description 17
239000002202 Polyethylene glycol Substances 0.000 description 15
239000003814 drug Substances 0.000 description 15
230000003902 lesion Effects 0.000 description 15
238000002560 therapeutic procedure Methods 0.000 description 15
229940079593 drug Drugs 0.000 description 14
230000004048 modification Effects 0.000 description 12
238000012986 modification Methods 0.000 description 12
239000006071 cream Substances 0.000 description 11
230000000694 effects Effects 0.000 description 11
229910052740 iodine Inorganic materials 0.000 description 11
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
229920003171 Poly (ethylene oxide) Polymers 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 10
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 10
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 9
230000009467 reduction Effects 0.000 description 9
239000012453 solvate Substances 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
238000005809 transesterification reaction Methods 0.000 description 9
206010015150 Erythema Diseases 0.000 description 8
239000007788 liquid Substances 0.000 description 8
229940068886 polyethylene glycol 300 Drugs 0.000 description 8
208000001840 Dandruff Diseases 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
239000013081 microcrystal Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
238000003756 stirring Methods 0.000 description 7
239000000725 suspension Substances 0.000 description 7
LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 description 6
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
206010046851 Uveitis Diseases 0.000 description 6
239000002253 acid Substances 0.000 description 6
239000000969 carrier Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
230000036576 dermal application Effects 0.000 description 6
231100000321 erythema Toxicity 0.000 description 6
239000003921 oil Substances 0.000 description 6
239000002674 ointment Substances 0.000 description 6
239000006186 oral dosage form Substances 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000136 polysorbate Polymers 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
238000007127 saponification reaction Methods 0.000 description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
206010003645 Atopy Diseases 0.000 description 5
201000004624 Dermatitis Diseases 0.000 description 5
206010012442 Dermatitis contact Diseases 0.000 description 5
101000845005 Macrovipera lebetina Disintegrin lebein-2-alpha Proteins 0.000 description 5
208000003251 Pruritus Diseases 0.000 description 5
239000004599 antimicrobial Substances 0.000 description 5
230000001363 autoimmune Effects 0.000 description 5
238000010586 diagram Methods 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
239000006185 dispersion Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
230000002500 effect on skin Effects 0.000 description 5
239000003925 fat Substances 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
230000006872 improvement Effects 0.000 description 5
239000011630 iodine Substances 0.000 description 5
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 5
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 5
229960002216 methylparaben Drugs 0.000 description 5
230000006911 nucleation Effects 0.000 description 5
238000010899 nucleation Methods 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
229940100688 oral solution Drugs 0.000 description 5
235000019271 petrolatum Nutrition 0.000 description 5
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 5
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 5
229960003415 propylparaben Drugs 0.000 description 5
208000017520 skin disease Diseases 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
235000015112 vegetable and seed oil Nutrition 0.000 description 5
239000008158 vegetable oil Substances 0.000 description 5
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 4
206010010741 Conjunctivitis Diseases 0.000 description 4
206010048768 Dermatosis Diseases 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
231100000360 alopecia Toxicity 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
208000010247 contact dermatitis Diseases 0.000 description 4
239000003995 emulsifying agent Substances 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
150000002170 ethers Chemical class 0.000 description 4
235000019197 fats Nutrition 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000000227 grinding Methods 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
239000008389 polyethoxylated castor oil Substances 0.000 description 4
238000000634 powder X-ray diffraction Methods 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
239000003871 white petrolatum Substances 0.000 description 4
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 3
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
208000009137 Behcet syndrome Diseases 0.000 description 3
206010012438 Dermatitis atopic Diseases 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
229920001214 Polysorbate 60 Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
238000013019 agitation Methods 0.000 description 3
230000002917 arthritic effect Effects 0.000 description 3
206010003246 arthritis Diseases 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
235000019445 benzyl alcohol Nutrition 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
230000008859 change Effects 0.000 description 3
239000007795 chemical reaction product Substances 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000004927 clay Substances 0.000 description 3
239000000470 constituent Substances 0.000 description 3
RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
229920001281 polyalkylene Polymers 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
229940068968 polysorbate 80 Drugs 0.000 description 3
230000001185 psoriatic effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000003826 tablet Substances 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 2
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
241000700198 Cavia Species 0.000 description 2
UYPPEWHLQQUDPM-UHFFFAOYSA-N Cyclosporin I Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)NC(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)C)NC1=O UYPPEWHLQQUDPM-UHFFFAOYSA-N 0.000 description 2
208000003556 Dry Eye Syndromes Diseases 0.000 description 2
206010013774 Dry eye Diseases 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000012659 Joint disease Diseases 0.000 description 2
208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 2
206010024438 Lichenification Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
235000019482 Palm oil Nutrition 0.000 description 2
235000019483 Peanut oil Nutrition 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
206010040867 Skin hypertrophy Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000000973 chemotherapeutic effect Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
239000006196 drop Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
229960003276 erythromycin Drugs 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
208000030533 eye disease Diseases 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
239000008394 flocculating agent Substances 0.000 description 2
230000002538 fungal effect Effects 0.000 description 2
230000035876 healing Effects 0.000 description 2
239000012051 hydrophobic carrier Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
230000036512 infertility Effects 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
230000036210 malignancy Effects 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
239000002540 palm oil Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000006072 paste Substances 0.000 description 2
239000000312 peanut oil Substances 0.000 description 2
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
229920001515 polyalkylene glycol Polymers 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
235000019422 polyvinyl alcohol Nutrition 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
238000000527 sonication Methods 0.000 description 2
239000001384 succinic acid Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000008719 thickening Effects 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical compound N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
241001550224 Apha Species 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
208000019838 Blood disease Diseases 0.000 description 1
QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007764 Cataract subcapsular Diseases 0.000 description 1
208000002691 Choroiditis Diseases 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229910016523 CuKa Inorganic materials 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
239000004606 Fillers/Extenders Substances 0.000 description 1
206010061958 Food Intolerance Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
201000002287 Keratoconus Diseases 0.000 description 1
206010066295 Keratosis pilaris Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010068773 Mechanical urticaria Diseases 0.000 description 1
208000019255 Menstrual disease Diseases 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
108010002885 Polygeline Proteins 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
208000003971 Posterior uveitis Diseases 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
MJOQJPYNENPSSS-XQHKEYJVSA-N [(3r,4s,5r,6s)-4,5,6-triacetyloxyoxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1CO[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O MJOQJPYNENPSSS-XQHKEYJVSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000001944 accentuation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
239000003904 antiprotozoal agent Substances 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
208000007287 cheilitis Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
201000000409 dermatographia Diseases 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000004821 distillation Methods 0.000 description 1
230000009429 distress Effects 0.000 description 1
239000008298 dragée Substances 0.000 description 1
201000002545 drug psychosis Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002996 emotional effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
208000020157 familial dermatographia Diseases 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000010437 gem Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
229940075507 glyceryl monostearate Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000005484 gravity Effects 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000007803 itching Effects 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000006651 lactation Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
238000002103 osmometry Methods 0.000 description 1
229940046781 other immunosuppressants in atc Drugs 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000037361 pathway Effects 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000019612 pigmentation Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
208000005069 pulmonary fibrosis Diseases 0.000 description 1
238000010298 pulverizing process Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008085 renal dysfunction Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
229960001225 rifampicin Drugs 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
229940063122 sandimmune Drugs 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
229940046303 sodium cetostearyl sulfate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
CLBALUNQCMWJSU-UHFFFAOYSA-L sodium;hexadecyl sulfate;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O CLBALUNQCMWJSU-UHFFFAOYSA-L 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
235000011078 sorbitan tristearate Nutrition 0.000 description 1
239000001589 sorbitan tristearate Substances 0.000 description 1
229960004129 sorbitan tristearate Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000035900 sweating Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000006257 total synthesis reaction Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1
210000002268 wool Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

DK198807054A 1987-12-21 1988-12-19 Ciclosporin, fremgangsmåde til fremstilling deraf, farmaceutisk præparat med indhold deraf samt dets anvendelse DK175220B1 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US13623087A	1987-12-21	1987-12-21
US13623087		1987-12-21
US17261388A	1988-03-24	1988-03-24
US17261388		1988-03-24
US21254888A	1988-06-28	1988-06-28
US21254888		1988-06-28

Publications (3)

Publication Number	Publication Date
DK705488D0 DK705488D0 (da)	1988-12-19
DK705488A DK705488A (da)	1989-06-22
DK175220B1 true DK175220B1 (da)	2004-07-12

Family

ID=27384838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198807054A DK175220B1 (da)	1987-12-21	1988-12-19	Ciclosporin, fremgangsmåde til fremstilling deraf, farmaceutisk præparat med indhold deraf samt dets anvendelse

Country Status (27)

Country	Link
JP (1)	JPH0791316B2 (fr)
KR (1)	KR100188305B1 (fr)
AT (1)	AT403163B (fr)
AU (1)	AU626274B2 (fr)
BE (1)	BE1002665A4 (fr)
CA (1)	CA1341396C (fr)
CH (1)	CH677926A5 (fr)
CY (1)	CY1799A (fr)
DE (1)	DE3843054C2 (fr)
DK (1)	DK175220B1 (fr)
ES (1)	ES2012580A6 (fr)
FI (1)	FI89065C (fr)
FR (1)	FR2624863B1 (fr)
GB (1)	GB2211848B (fr)
GR (1)	GR1002486B (fr)
HK (1)	HK102894A (fr)
HU (1)	HU203564B (fr)
IE (1)	IE62006B1 (fr)
IL (1)	IL88719A0 (fr)
IT (1)	IT1235356B (fr)
LU (1)	LU87409A1 (fr)
MY (1)	MY103943A (fr)
NL (1)	NL195096C (fr)
NO (1)	NO177228C (fr)
NZ (1)	NZ227384A (fr)
SE (1)	SE503174C2 (fr)
SG (1)	SG99494G (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US7081445B2 (en)	1989-02-20	2006-07-25	Novartis Ag	Cyclosporin galenic forms
US5294604A (en) *	1989-12-20	1994-03-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating ocular diseases by periocular administration of cyclosporine A or G
GB9105705D0 (en) *	1991-03-18	1991-05-01	Sandoz Ltd	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en) *	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
ES2177652T3 (es)	1994-11-03	2002-12-16	Novartis Ag	Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5766629A (en)	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
US6262054B1 (en)	1996-02-01	2001-07-17	Sloan-Kettering Institute Of Cancer Research	Combination therapy method for treating breast cancer using edatrexate
KR20050084502A (ko)	1997-01-30	2005-08-26	노파르티스 아게	오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
TW581681B (en)	1998-02-20	2004-04-01	Nektar Therapeutics	Liquid crystal forms of cyclosporin
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
CN100548271C (zh)	2004-01-20	2009-10-14	阿勒根公司	用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
CN1763084B (zh) *	2005-10-11	2010-04-21	山东新时代药业有限公司	高纯度环孢菌素a的制备方法
BR112013030554B1 (pt) *	2011-05-27	2020-12-15	Allergan, Inc.	Forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
RU2641963C2 (ru) *	2011-11-15	2018-01-23	Аллерган, Инк.	Взвеси циклоспорина а формы 2
US20130123194A1 (en) *	2011-11-15	2013-05-16	Allergan, Inc.	Autoclavable suspensions of cyclosporin a form 2
CA2856034C (fr) *	2011-11-15	2017-12-12	Allergan, Inc.	Forme 2 de cyclosporine a et methode de fabrication associee
US8785394B2 (en) *	2011-11-15	2014-07-22	Allergan, Inc.	Sustained action formulation of cyclosporin form 2
TW202430537A (zh) *	2022-10-20	2024-08-01	日商中外製藥股份有限公司	環狀胜肽的結晶的製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH614931A5 (fr) *	1975-11-04	1979-12-28	Sandoz Ag
CH640519A5 (en) *	1976-04-09	1984-01-13	Sandoz Ag	Process for preparing a modified form of the antibiotic S 7481/F-1
US4117118A (en) *	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DE2819094A1 (de) *	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
CH637124A5 (en) *	1978-10-18	1983-07-15	Sandoz Ag	Antibiotic, its preparation and use

1988
- 1988-12-09 HU HU886374A patent/HU203564B/hu unknown
- 1988-12-19 NO NO885625A patent/NO177228C/no unknown
- 1988-12-19 AU AU27055/88A patent/AU626274B2/en not_active Expired
- 1988-12-19 FI FI885869A patent/FI89065C/fi not_active IP Right Cessation
- 1988-12-19 IE IE377988A patent/IE62006B1/en not_active IP Right Cessation
- 1988-12-19 CH CH4687/88A patent/CH677926A5/de not_active IP Right Cessation
- 1988-12-19 SE SE8804570A patent/SE503174C2/sv not_active IP Right Cessation
- 1988-12-19 NZ NZ227384A patent/NZ227384A/xx unknown
- 1988-12-19 DK DK198807054A patent/DK175220B1/da not_active IP Right Cessation
- 1988-12-19 IL IL88719A patent/IL88719A0/xx unknown
- 1988-12-19 FR FR888816886A patent/FR2624863B1/fr not_active Expired - Lifetime
- 1988-12-19 GB GB8829556A patent/GB2211848B/en not_active Expired - Lifetime
- 1988-12-20 LU LU87409A patent/LU87409A1/fr unknown
- 1988-12-20 KR KR1019880017194A patent/KR100188305B1/ko not_active Expired - Lifetime
- 1988-12-20 IT IT8848690A patent/IT1235356B/it active
- 1988-12-20 BE BE8801421A patent/BE1002665A4/fr not_active IP Right Cessation
- 1988-12-20 JP JP63321857A patent/JPH0791316B2/ja not_active Expired - Lifetime
- 1988-12-20 AT AT0309588A patent/AT403163B/de not_active IP Right Cessation
- 1988-12-20 GR GR880100850A patent/GR1002486B/el not_active IP Right Cessation
- 1988-12-21 CA CA000586611A patent/CA1341396C/fr not_active Expired - Fee Related
- 1988-12-21 DE DE3843054A patent/DE3843054C2/de not_active Expired - Lifetime
- 1988-12-21 NL NL8803125A patent/NL195096C/nl active Search and Examination
- 1988-12-21 ES ES8803887A patent/ES2012580A6/es not_active Expired - Lifetime
- 1988-12-21 MY MYPI88001495A patent/MY103943A/en unknown
1994
- 1994-07-21 SG SG99494A patent/SG99494G/en unknown
- 1994-09-22 HK HK102894A patent/HK102894A/xx not_active IP Right Cessation
1995
- 1995-02-17 CY CY179995A patent/CY1799A/en unknown

Also Published As

Publication number	Publication date
NZ227384A (en)	1991-09-25
DK705488A (da)	1989-06-22
CH677926A5 (fr)	1991-07-15
LU87409A1 (fr)	1989-07-07
NL195096C (nl)	2004-02-09
JPH01211598A (ja)	1989-08-24
FR2624863A1 (fr)	1989-06-23
IT8848690A0 (it)	1988-12-20
SE8804570D0 (sv)	1988-12-19
KR100188305B1 (ko)	1999-06-01
BE1002665A4 (fr)	1991-04-30
GR1002486B (el)	1996-12-09
GR880100850A (el)	1994-03-31
MY103943A (en)	1993-10-30
HK102894A (en)	1994-09-30
IT1235356B (it)	1992-06-30
CY1799A (en)	1995-02-17
CA1341396C (fr)	2002-11-05
NL8803125A (nl)	1989-07-17
AT403163B (de)	1997-11-25
ES2012580A6 (es)	1990-04-01
JPH0791316B2 (ja)	1995-10-04
FR2624863B1 (fr)	1991-04-26
NO885625D0 (no)	1988-12-19
GB2211848B (en)	1991-11-06
ATA309588A (de)	1997-04-15
FI885869A0 (fi)	1988-12-19
FI89065C (fi)	1993-09-30
SE8804570L (sv)	1989-06-22
DE3843054A1 (de)	1989-07-27
AU626274B2 (en)	1992-07-30
DK705488D0 (da)	1988-12-19
NO885625L (no)	1989-06-22
SE503174C2 (sv)	1996-04-15
IL88719A0 (en)	1989-07-31
IE62006B1 (en)	1994-12-14
AU2705588A (en)	1989-06-22
FI885869L (fi)	1989-06-22
FI89065B (fi)	1993-04-30
IE883779L (en)	1989-06-21
KR890009975A (ko)	1989-08-05
SG99494G (en)	1994-10-28
HUT49893A (en)	1989-11-28
NO177228B (no)	1995-05-02
DE3843054C2 (de)	2003-08-21
NO177228C (no)	1995-08-09
HU203564B (en)	1991-08-28
GB8829556D0 (en)	1989-02-08
GB2211848A (en)	1989-07-12

Legal Events

Date	Code	Title	Description
2009-01-19	PUP	Patent expired

Publication	Publication Date	Title
KR100188305B1 (ko)	1999-06-01	신규의 시클로스포린 결정 형태, 이것의 제조 방법 및 이것을 함유한 약학 조성물 및 그 용도
NL194781C (nl)	2003-03-04	Farmaceutisch preparaat voor orale toediening dat een cyclosporine bevat.
SE511398C2 (sv)	1999-09-20	Komposition innehållande cyklosporin och sackaros- eller raffinosmonolaurat
JP3090666B2 (ja)	2000-09-25	薬理活性化合物および医薬賦形剤用可溶化剤としての水溶性モノエステル類
KR102007731B1 (ko)	2019-08-06	티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법
JP2011105754A (ja)	2011-06-02	シクロスポリンの投与のための親水性二成分系
JP2003510267A (ja)	2003-03-18	医薬担体処方
CZ279654B6 (cs)	1995-05-17	Způsob výroby cyklosporinu A
HU212727B (en)	1996-10-28	Process for producing pharmaceutical compositions in form of microemulsion-prae-concentrate or microemulsion containing cyclosporin(s) as active component